Back to Aptus Capital Advisors, LLC Aptus Capital Advisors, LLC

XLOXLO

5 quarters

Position history for Aptus Capital Advisors, LLCAptus Capital Advisors, LLC's holdings in Xilio Therapeutics, Inc.

No. Aptus Capital Advisors exited its XLO (Xilio Therapeutics) position in Q4 2025. Its Q3 2025 13F listed 25,000 shares worth $21,068. Aptus Capital Advisors first reported XLO in Q4 2024 and held it in 4 quarterly 13F filings.

Final Value

$0

Final Shares

0

Total Value Change

-$39,155

Total Shares Change

-41,000

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2025-Q4
Latest
Exited
0
-100.0%
$00.0%$8.96
0
2025-Q3
Unchanged
25,000
0.0%
$21,0680.0%$11.80
0
2025-Q2
Decreased
25,000
-45.6%
$16,9980.0%$9.52
0
2025-Q1
Increased
46,000
+12.2%
$33,3220.0%$10.14
22
2024-Q4
New
41,000
—
$39,1550.0%$13.37
28

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used